SILEXION THERAPEUTICS CORP Research and Development Expense
SILEXION THERAPEUTICS CORP (SLXN) reported Research and Development Expense of $2.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- SILEXION THERAPEUTICS CORP research and development expense for the quarter ending 2026-06-30 was $2.21M, a 117.29% increase year-over-year.
- SILEXION THERAPEUTICS CORP research and development expense for the quarter ending 2026-03-31 was $1.37M, a 132.20% increase year-over-year.
- SILEXION THERAPEUTICS CORP research and development expense for the quarter ending 2025-12-31 was $3.38M, a 287.49% increase year-over-year.
- SILEXION THERAPEUTICS CORP research and development expense for the quarter ending 2025-09-30 was $2.16M, a 32.95% decline year-over-year.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.21M 10-Q · filed 2026-08-14 | $3.58M 10-Q · filed 2026-08-14 | $6.96M derived: sum of 3 quarters · filed 2026-08-14 | $9.11M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.37M S-1/A · filed 2026-08-10 | $4.75M derived: sum of 2 quarters · filed 2026-08-10 | $6.90M derived: sum of 3 quarters · filed 2026-08-10 | $7.92M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $3.38M derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-10 | $5.53M derived: sum of 2 quarters · filed 2026-08-10 | $6.55M derived: sum of 3 quarters · filed 2026-08-14 | $7.14M S-1/A · filed 2026-08-10 |
| 2025-09-30 | $2.16M 10-Q · filed 2025-11-12 | $3.17M derived: sum of 2 quarters · filed 2026-08-14 | $3.77M 10-Q · filed 2025-11-12 | $4.64M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.02M 10-Q · filed 2026-08-14 | $1.61M 10-Q · filed 2026-08-14 | $2.48M derived: sum of 3 quarters · filed 2026-08-14 | $5.70M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $590.00K S-1/A · filed 2026-08-10 | $1.46M derived: sum of 2 quarters · filed 2026-08-10 | $4.68M derived: sum of 3 quarters · filed 2026-08-10 | $5.44M derived: sum of 4 quarters · filed 2026-08-10 |
| 2024-12-31 | $871.00K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-10 | $4.09M derived: sum of 2 quarters · filed 2026-08-10 | $4.85M derived: sum of 3 quarters · filed 2026-08-10 | $5.82M S-1/A · filed 2026-08-10 |
| 2024-09-30 | $3.22M 10-Q · filed 2025-11-12 | $3.98M derived: sum of 2 quarters · filed 2025-11-12 | $4.94M 10-Q · filed 2025-11-12 | $6.20M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $766.00K 10-Q · filed 2025-08-12 | $1.73M 10-Q · filed 2025-08-12 | $2.98M derived: sum of 3 quarters · filed 2025-08-20 | $3.52M derived: sum of 4 quarters · filed 2025-08-20 |
| 2024-03-31 | $961.00K 10-Q · filed 2025-05-13 | $2.22M derived: sum of 2 quarters · filed 2025-08-20 | $2.75M derived: sum of 3 quarters · filed 2025-08-20 | $3.99M derived: sum of 4 quarters · filed 2025-08-20 |
| 2023-12-31 | $1.26M derived: 8-K 12 month − 10-Q 9 month · filed 2025-08-20 | $1.79M derived: sum of 2 quarters · filed 2025-08-20 | $3.03M derived: sum of 3 quarters · filed 2025-08-20 | $3.71M 8-K · filed 2025-08-20 |
| 2023-09-30 | $535.00K 10-Q · filed 2024-11-14 | $1.77M derived: sum of 2 quarters · filed 2024-11-14 | $2.45M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $1.24M 10-Q · filed 2024-08-29 | $1.92M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |